Tuberculosis Vaccine Development: Progress in Clinical Evaluation

Area of Science:

• Infectious diseases and vaccinology.
• Immunology and microbiology of tuberculosis.

Background:

• Tuberculosis (TB) remains a leading global infectious killer, with the current bacille Calmette-Guérin (BCG) vaccine having limitations.
• Despite extensive research, a highly effective and safe TB vaccine is urgently needed to prevent infection, disease, and recurrence.

Purpose of the Study:

• To review current understanding of natural immunity to TB and limitations of BCG.
• To outline desired attributes for modern TB vaccines.
• To provide an overview of TB vaccine candidates in clinical trials and future research directions.

Main Methods:

• Review of scientific literature on TB immunology, vaccine platforms, and clinical trial data.
• Analysis of efficacy signals from recent phase 2b clinical trials.
• Synthesis of knowledge on TB infection spectrum and immunology.

Main Results:

• Recent phase 2b clinical trials observed efficacy signals for novel TB vaccine candidates in adolescents and infected adults.
• Expanded knowledge of TB immunology and infection spectrum is driving innovative vaccine design.
• The TB vaccine field is reinvigorated by these promising developments.

Conclusions:

• Novel TB vaccine candidates show potential for improved efficacy over BCG.
• Continued research and development are crucial to accelerate the trajectory of TB vaccine R&D.
• Building on recent successes is key to developing a modern, effective TB vaccine.